NCT02121509 Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects Status COMPLETED Phase PHASE1
NCT02121483 Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus Status COMPLETED Phase PHASE1
NCT02111096 A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus Status TERMINATED Phase PHASE2
NCT02111083 A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants Status COMPLETED Phase PHASE1
NCT02109042 A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants Status COMPLETED Phase PHASE1
NCT02109029 A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue Status COMPLETED Phase PHASE1
NCT02107703 A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02106923 Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets Status COMPLETED Phase PHASE1
NCT02106364 A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus Status WITHDRAWN Phase PHASE3
NCT02104765 A Study of LY2951742 in Healthy Japanese and Caucasian Participants Status COMPLETED Phase PHASE1
NCT02102932 Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers Status COMPLETED Phase PHASE1
NCT02102490 A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Status COMPLETED Phase PHASE2
NCT02095288 Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A Status ACTIVE_NOT_RECRUITING Phase N/A
NCT02091362 A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus Status COMPLETED Phase PHASE2
NCT02084082 Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects Status COMPLETED Phase PHASE1
NCT02084056 Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects. Status COMPLETED Phase PHASE1